RT Journal Article
SR Electronic
T1 Monitoring of SARS-CoV-2 B.1.1.7 variant early-phase spreading in South-Moravian Region in the Czech Republic and evaluation of its pathogenicity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.24.21257365
DO 10.1101/2021.05.24.21257365
A1 Daniel Diabelko
A1 Milada Dvorackova
A1 Monika Dvorakova Heroldova
A1 Giancarlo Forte
A1 Ivan Cundrle
A1 Filip Ruzicka
A1 Jan Vrbsky
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.05.24.21257365.1.abstract
AB SARS-CoV-2 emerged in Wuhan, China, in December 2019. Starting in January 2020, over a period of several months, the initial virus (Wuhan-Hu-1/2019; Wu et al. 2020) diverged in a descendant strain carrying D614G amino acid mutation in spike protein. By summer 2020 this novel coronavirus (nCoV) became the most dominant form of the virus circulating worldwide and raised serious international concern. Currently (April 2021), there are 3598 subsequent PANGO branched lineages recognized that carry numerous mutations. To date, the most emerging lineages of SARS-CoV-2 worldwide include B.1.1.7 lineage with a frequency of 48% followed by several dozens of others with frequencies 7.5% or less, such as B.1.351, B.1.1.28, B.1.2, B.1.1.519, P.1, R.1, etc. (www.nextrain.org, Centers for Disease Control and Prevention; CDC 2020 www.cdc.gov).In this study, we monitored the spreading of B.1.1.7 lineage from the early phase of its appearance until it became predominant in the South-Moravian region of the Czech Republic. We measured significantly associated clinical marker (Ct; cycle threshold) correlating with viral load in B.1.1.7 lineage. Interestingly, we found that the spreading of B.1.1.7 strain was associated with a shift in patients average age, as compared to the former predominant lineage. Finally, we calculated the impact of the B.1.1.7 lineage on hospitalization and case fatality of the patients on the intensive care unit in the central South-Moravian faculty hospital.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEuropean Regional Development Fund - Project MAGNET (No. CZ.02.1.01/0.0/0.0/15_003/0000492), Ministry of Health Research Programme NU21J-05-00035Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Opinion of the Ethics Committee For Consent to the Publication of the Study was approved at 24th of May 2021, signed by Chairperson of the EC St. Anne University Hospital Brno. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.